Gsk Plc · LSE:GSK
Gsk — GSK Consumer Healthcare Pakistan — Investor Presentation (2020)
24 slides from Gsk's investor presentation, 2020
Slide 1: Corporate Briefing Session
Corporate Briefing Session GSK Consumer Healthcare Pakistan Limited
Slide 2: Agenda
Agenda Company Brief and Key Facts Our Vision, Values and Strategy Key Financials Questions and Answers 2
Slide 3: Company Brief and Key Facts
Company Brief and Key Facts
Slide 4: Company Brief and Key Facts
Company Brief and Key facts GSK Consumer business demerged from GSK Pakistan Limited in 2015 and formed two entities; • GSK Consumer Healthcare Pakistan Limited (GSK CHC) and • GSK OTC Private Limited (GSK OTC) (carved out of the GSK-Novartis JV) Transfer of Marketing GSK CHC starts operations as Au
Slide 5: Board Committees & Key Roles
Board Committees & Key Roles Human Resource and Integration Supply & Audit Committee Remuneration Network Optimization Management Committee Committee Committee • Syed Anwar Mahmood (Chairman) • Syed Anwar Mahmood (Chairman) • Oussama Abbas (Chairman) • Sohail Ahmed Matin (CEO) • M.Z. Moin Mohajir •
Slide 6: Our Local Footprint
Our Local Footprint Registered Office: 35-Dockyard Road, West Wharf, Karachi Sales Offices: Karachi – B 63, 65, Estate Avenue, SITE Lahore – 880 B, Faisal Town Islamabad – Aleem House, Plot 409, Sector I9, West Wharf Office Industrial Area Factory: • GSK CHC acquired the manufacturing facility of GS
Slide 7: Brands Portfolio
Brands Portfolio FMCG OVER THE COUNTER (Regulated by DRAP) (Represents 16% business) (Represents 84% business) Nutrition & Skin Health Respiratory Pain Relief Oral Care Skin Health Digestive 7
Slide 8: Industry Landscape
Industry Landscape TOP 10 Corporates — MAT Q3 2020. Industry Growth: 10.31% CS ne 33,436 7.20 CEL ee 30,474 12.05 ABBOTT a 29,750 13.48 SEARLE Es 28,085 17.31 SAM ee 26,775 16.63 MARTIN DOW 21,009 16.95 GSK CH SE 16,017 26.66 HCH-Q Ts 15,197 3.95 HILTON SE 14,007 3.05 BOSCH EET 13,573 9.69 Value :Mn
Slide 9: Our Vision, Values and Strategy
Our Vision, Values and Strategy
Slide 10: Customer First
Our Values & Expectations are at the Heart of Everything We Do Customer First 10
Slide 11: Our Purpose, Vision and Strategy
Our Purpose, Vision and Strategy Purpose To help people do more, feel better, live longer Vision To be one of the world’s most innovative, best performing and trusted consumer healthcare companies Strategy Innovation Performance Trust • Brilliant execution of Sustained industry-leading • Reliable su
Slide 12: Innovations
Innovations Panadol CF Day Sensodyne Herbal Parodontax Herbal Expanding the Respiratory Business Entering the growing Herbal Segment in Oral Health Category
Slide 13: Key Brands Performance
Key Brands Performance Top 3 Brands contribute 81% to Total turnover in Pain Relief Category Prescribed Calcium supplement in Sensitivity Category 42% Contribution 27% Contribution 13% Contribution GSK Share 21.5% GSK Share 45.3% GSK Share 16.5% 17% Volume Growth 21%Volume Growth 12% Volume Growth C
Slide 14: Key Campaigns
Key Campaigns Panadol Calcium Awareness Sensodyne Launched #1000WaysICan campaign Drove Sensodyne Panadol Lady Doctor to drive top of mind awareness Herbal on multiple Campaign keeping brand platforms for max top of mind for consumers reach and conversions Always-On Digital to build reach, relevance
Slide 15: Key Performance Highlights and Trust Factors
Key Performance Highlights and Trust Factors • Delivered 23% sales growth during first nine months ending September 2020. • Captured overall Market share of *17.7% in total operating market. +2.4% vs LY • Increased Oral Care numeric distribution by driving smaller size SKUs in General Trade. • Evolv
Slide 16: GSK CH's response to COVID
GSK CH’s response to COVID Response in COVID People Safety Supply Chain Operations Quickly responded to changing Ensured team and front line workers Put customers & consumers market dynamics were safe first Work from Home + Covid Awareness Electronic Approval Strong BCPs put in place campaign proces
Slide 17: Key Financial
Key Financial
Slide 18: Key Financial Highlights
Key Financial Highlights YTD September 2020 (2% vs LY) (12% vs LY) Net Sales Growth in Sales Gross margin *OPEX Profit before tax Earning per share 14,489 23% 28% 2,603 1,381 Million Million million Rs. 8.32 YTD September 2019 Net Sales Gross margin OPEX Profit before tax Earning per share 11,812 32
Slide 19: Portfolio wise Sales – Sept YTD
Portfolio wise Sales – Sept YTD Amounts in PKR million Net Company - Sales 23% increase at total Net Sales - OTC Company level Portfolio 25% increase over last year Net Sales - FMCG Portfolio Net Sales - Toll *3% increase over (Novartis) 14,489 last year 10,844 37% increase over 11,812 8,668 last ye
Slide 20: Sales Contribution – Sept YTD
Sales Contribution – Sept YTD Portfolio wise - Share 2019: PORTFOLIO SHARE 2020: PORTFOLIO SHARE Toll Mfg - Toll Mfg - Export , 2.7% Novartis, 11.4% Export , 0.1% Novartis, 10.2% FMCG Portfolio, FMCG Portfolio, 13.8% 16.4% OTC Portfolio, 70.7% OTC Portfolio, 74.7% 20
Slide 21: Revenue Distribution
Revenue Distribution To Shareholders, 4% Retained in the Business, 3% To Employees, 7% To Government, 6% Administrative expenses and financial charges , 1% Selling, marketing and Bought-in -materials and distribution expenses, 13% Services , 67% 21
Slide 22: Key Performance Ratios
Key Performance Ratios Balance Sheet Ratios September 30, September 30, 2020 2019 Return on equity 20% 21% Current Ratio 1.36 1.37 Quick Ratio 0.61 0.67 Inventory days 87 82 Receivables days 17 17 Payable days 21 24 22
Slide 23: Outlook and Challenges
Outlook and Challenges Unceasing spike in COVID cases, new regulations by government. Ultimate severity, duration and impact of the pandemic remain unknown. Continuous currency devaluation negatively impacting the ability of business to distribute and invest more. Face to face meetings with doctors
Slide 24: Thank You! Q&A
THANK YOU! Q&A
GSK Consumer Healthcare Pakistan — Investor Presentation (2020) on 6ix